Search Results

• • 15 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Molecular profiling is not the future: it is now!

  From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20151,350 words Interview 1450LAuthor(s): Bobby Reddy [*] aff1 aff2 KEYWORDS Caris Life Sciences; cancer biomarkers; cancer research; molecular profiling; luminal breast cancer; male breast cancer; PD-1; personalized medicine; PD-L1; precision...

• Buparlisib in breast cancer

  Authors:Bhawna Sirohi, Sameer Rastogi, and Shaheenah DawoodFrom:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20155,450 words Report 1870LAuthor(s): Bhawna Sirohi [*] aff1 , Sameer Rastogi aff2 , Shaheenah Dawood aff3 KEYWORDS breast cancer; buparlisib; mTOR; PI3K Metastatic breast cancer, either diagnosed at initial presentation or diagnosed...

• The role of primary endocrine therapy in older women with operable breast cancer

  Authors:Simon J Johnston and Kwok-Leung CheungFrom:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20155,797 words Report 1760LAuthor(s): Simon J Johnston aff1 , Kwok-Leung Cheung [*] aff1 KEYWORDS anastrozole; aromatase inhibitor; breast cancer; estrogen receptor positive; older women; primary endocrine therapy; surgery; tamoxifen...

• Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer

  Author:Leigh EllisFrom:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20152,223 words Report 2010LAuthor(s): Leigh Ellis [*] KEYWORDS aggressive prostate cancer; epigenetics; ezh2; metastasis; precision medicine; targeted therapy; topoisomerase Emergence of aggressive prostate cancer (PCa) phenotypes...

• Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer

  Authors:Bhawna Sirohi, Abhishek Mitra, Palepu Jagannath, Ashish Singh, Mukta Ramadvar, Suyash Kulkarni, et al.From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20154,161 words Report 1630LAuthor(s): Bhawna Sirohi [*] aff1 , Abhishek Mitra aff2 , Palepu Jagannath aff3 , Ashish Singh aff1 , Mukta Ramadvar aff4 , Suyash Kulkarni aff5 , Mahesh Goel aff2 , Shailesh V Shrikhande aff2 KEYWORDS gallbladder...

• A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors

  Authors:Michael S Gordon, Gregory M Springett, Yungpo Bernard Su, Mahmoud Ould-Kaci, Sven Wind, Yihua Zhao, et al.From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20157,877 words Report 1680LAuthor(s): Michael S Gordon [*] aff1 , Gregory M Springett aff2 , Yungpo Bernard Su aff3 , Mahmoud Ould-Kaci aff4 , Sven Wind aff5 , Yihua Zhao aff6 , Patricia M LoRusso aff7 aff8 KEYWORDS afatinib; BIBF 1120;...

• The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia

  Authors:Mehdi Yousefi, Ali Akbar Movassaghpour, Karim Shamsasenjan, Ghasem Ghalamfarsa, Sanam Sadreddini, Farhad Jadidi-Niaragh, et al.From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 201512,925 words Report 2250LAuthor(s): Mehdi Yousefi aff1 aff2 , Ali Akbar Movassaghpour aff3 , Karim Shamsasenjan aff3 , Ghasem Ghalamfarsa aff4 , Sanam Sadreddini aff1 , Farhad Jadidi-Niaragh [*] aff5 , Mohammad Hojjat-Farsangi aff6 KEYWORDS...

• Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?

  Authors:Jianbo Li, Guojian Zhang, Xuemei Wang, and Xiao-Feng LiFrom:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20155,910 words Report 1970LAuthor(s): Jianbo Li aff1 aff2 , Guojian Zhang aff1 aff2 , Xuemei Wang [*] aff1 , Xiao-Feng Li [*] aff2 KEYWORDS cancer; carbonic anhydrase IX; hypoxia; molecular imaging In 2013, approximately 1,660,290 new...

• Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

  Authors:Patrick M Reagan and Jonathan W FriedbergFrom:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20158,455 words Report 1560LABSTRACT Radioimmunotherapy is an effective treatment modality with an acceptable toxicity profile in both indolent B-cell non-Hodgkin lymphoma and histologic transformation. Its ease of administration from a patient's...

• Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients

  Authors:G Mustacchi, F Puglisi, AM Molino, D Crivellari, C Ghiotto, A Ferro, et al.From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20154,980 words Report 1610LAuthor(s): G Mustacchi [*] aff1 , F Puglisi aff2 , AM Molino aff3 , D Crivellari aff4 , C Ghiotto aff5 , A Ferro aff6 , A Brunello aff7 , S Saracchini aff8 , M Turazza aff9 , E Cretella aff10 , A Iop aff11 , M Malagoli...

• Circulating free DNA in plasma or serum as biomarkers of carcinogenesis in colon cancer

  Authors:Alberto Mangano, Alessandro Mangano, Georgios D Lianos, Elisa Cassinotti, Dimitrios H Roukos, Gianlorenzo Dionigi, et al.From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20152,402 words Report 1890LAuthor(s): Alberto Mangano [*] aff1 , Alessandro Mangano aff2 , Georgios D Lianos aff3 , Elisa Cassinotti aff4 , Dimitrios H Roukos aff3 , Gianlorenzo Dionigi aff1 , Luigi Boni aff4 KEYWORDS biomarkers; cancer...

• Corrigendum

  From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 2015221 words Brief article, Corre... 1510LFollowing publication of the Drug Evaluation by Courtney D DiNardo, Susan O'Brien, Varsha V Gandhi & Farhad Ravandi titled 'Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia, which appeared in the...

• Surgery for liver metastases from breast cancer

  Authors:Petros Charalampoudis, Dimitrios Mantas, Georgios C Sotiropoulos, Dimitrios Dimitroulis, Gregory Kouraklis, and Christos MarkopoulosFrom:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20156,934 words Report 1690LAuthor(s): Petros Charalampoudis [*] aff1 , Dimitrios Mantas aff1 , Georgios C Sotiropoulos aff1 , Dimitrios Dimitroulis aff1 , Gregory Kouraklis aff1 , Christos Markopoulos aff1 KEYWORDS breast cancer;...

• The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer

  Authors:Masato Nakamura, Yasuhide Yamada, Kei Muro, Keiichi Takahashi, Hideo Baba, Yasutsuna Sasaki, et al.From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20155,079 words Report 1580LAuthor(s): Masato Nakamura [*] aff1 , Yasuhide Yamada aff2 , Kei Muro aff3 , Keiichi Takahashi aff4 , Hideo Baba aff5 , Yasutsuna Sasaki aff6 , Yoshito Komatsu aff7 , Taroh Satoh aff8 , Hideyuki Mishima aff9 , Masahiko...

• Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations - example of EVESOR trial

  Authors:Mevidette El-Madani, Emilie Henin, Thibaud Lefort, Michel Tod, Gilles Freyer, Philippe Cassier, et al.From:Future Oncology (Vol. 11, Issue 10) Peer-Reviewed

  May 20154,324 words Report 1600LAuthor(s): Mevidette El-Madani aff1 aff2 , Emilie Hénin aff1 aff3 , Thibaud Lefort aff4 , Michel Tod aff1 , Gilles Freyer aff1 aff5 , Philippe Cassier aff6 , Pierre-Jean Valette aff4 , Claire Rodriguez-Lafrasse aff1...